Evidence map›Paper›PMID 22298121›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2012

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.

Lobna Ibrahim, Nancy Diazgranados, Jose Franco-Chaves, Nancy Brutsche, Ioline D Henter, Phillip Kronstein, Ruin Moaddel, Irving Wainer, David A Luckenbaugh, Husseini K Manji and 1 more

Open access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 152 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
152citing papers in PubMed, 7 pooled it
30.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

152 citing papers in PubMed, 7 syntheses or guidelines pooled it, 306 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Ketamine for Bipolar Depression: A Systematic Review.The international journal of neuropsychopharmacology · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Modulation of early non-rapid eye movement slow wave activity by ketamine in treatment-resistant depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

92 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Lobna IbrahimExperimental Therapeutics and Pathophysiology Branch, Division of Intramural Research Programs, National Institute of Mental Health-NIMH, National Institutes of Health-NIH, Bethesda, MD, USA.
Nancy Diazgranados
Jose Franco-Chaves
Nancy Brutsche
Ioline D Henter
Phillip Kronstein
Ruin Moaddel
Irving Wainer
David A Luckenbaugh
Husseini K Manji
Carlos A Zarate
National Institutes of Health · USJohnson & Johnson (United States) · USNational Institute of Mental Health · USThe University of Texas Health Science Center at San Antonio · US

Funding

Disease Status Drug Metabolism and New Drug Discovery ZIAAG000297 · NIA · NATIONAL INSTITUTE ON AGING · PI EGAN, JOSEPHINE · 2009 to 2025
$38.2M
Efficacy of an Antiglutamatergic Agents in Treatment-Resistant DepressionZIAMH002828 · NIMH · NATIONAL INSTITUTE OF MENTAL HEALTH · PI ZARATE, CARLOS · 2009 to 2014
$1.6M
Intramural NIH HHS
6 · The paper itself

Abstract

The N-methyl-D-aspartate antagonist ketamine has rapid antidepressant effects in patients with treatment-resistant major depression (TRD); these effects have been reported to last for 1 week in some patients. However, the extent and duration of this antidepressant effect over longer periods has not been well characterized under controlled conditions. Riluzole, a glutamatergic modulator with antidepressant and synaptic plasticity-enhancing effects, could conceivably be used to promote the antidepressant effects of ketamine. This study sought to determine the extent and time course of antidepressant improvement to a single-ketamine infusion over 4 weeks, comparing the addition of riluzole vs placebo after the infusion. Forty-two subjects (18-65) with TRD and a Montgomery-Asberg Depression Rating Scale (MADRS) score of ≥ 22 received a single intravenous infusion of ketamine (0.5 mg/kg). Four to six hours post-infusion, subjects were randomized to double-blind treatment with either riluzole (100-200 mg/day; n=21) or placebo (n=21) for 4 weeks. Depressive symptoms were rated daily. A significant improvement (P<0.001) in MADRS scores from baseline was found. The effect size of improvement with ketamine was initially large and remained moderate throughout the 28-day trial. Overall, 27% of ketamine responders had not relapsed by 4 weeks following a single ketamine infusion. The average time to relapse was 13.2 days (SE=2.2). However, the difference between the riluzole and placebo treatment groups was not significant, suggesting that the combination of riluzole with ketamine treatment did not significantly alter the course of antidepressant response to ketamine alone.

Indexed as

AdolescentAdultAgedDepressionDouble-Blind MethodExcitatory Amino Acid AntagonistsFemaleFollow-Up StudiesHumansInfusions, IntravenousKetamineMaleMiddle AgedOutcome Assessment, Health CarePsychiatric Status Rating ScalesRiluzoleExcitatory Amino Acid AntagonistsKetaminenorketamineRiluzole

Identifiers

PMID22298121
PMCPMC3327857
OpenAlexW2006861654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.